Another study suggested that ACTL6A suppressed p21(Cip1) promoter activity to reduce p21Cip1 protein expression, which was a mechanism to maintain the aggressive phenotype of epidermal squamous cell carcinoma 14
[9] [10] FDA warnings include risks of pancreatitis and gallbladder disease
AT A GLANCE Originally FDA-approved for type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) also lead to sustained weight loss and have revolutionized diabetes and obesity management
GLP-1 receptor agonists also slow gastric emptying, reduce appetite through central nervous system pathways, and promote satiety, leading to reduced caloric intake and weight loss
In that report, the incidence of pancreatic cancer was also 2.9 and 2.7 times greater with exenatide and sitagliptin, respectively, compared to other oral antidiabetic medications
Our licensed medical team reviews your health history and wellness goals to ensure your treatment is tailored specifically to you